Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme

INTRODUCTION: In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimutai, Robert, Musa, Ahmed M., Njoroge, Simon, Omollo, Raymond, Alves, Fabiana, Hailu, Asrat, Khalil, Eltahir A. G., Diro, Ermias, Soipei, Peninah, Musa, Brima, Salman, Khalid, Ritmeijer, Koert, Chappuis, Francois, Rashid, Juma, Mohammed, Rezika, Jameneh, Asfaw, Makonnen, Eyasu, Olobo, Joseph, Okello, Lawrence, Sagaki, Patrick, Strub, Nathalie, Ellis, Sally, Alvar, Jorge, Balasegaram, Manica, Alirol, Emilie, Wasunna, Monique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/
https://www.ncbi.nlm.nih.gov/pubmed/28066878
http://dx.doi.org/10.1007/s40261-016-0481-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315726/
https://www.ncbi.nlm.nih.gov/pubmed/28066878
http://dx.doi.org/10.1007/s40261-016-0481-0

Ejemplares similares